NCT06027086
DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
StatusActive, Not Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 41 words Show 4 more changesShow less
- Enrollment closed, study ongoing
- Final enrollment: 6 participants (planned 27)
- Secondary endpoints: details revised at 2 of 2 entries
- Site details revised
- Minor Site contact updatedv7
- Minor Primary completion date: Aug 1, 2028 to Sep 1, 2028
- Study completion date: Aug 1, 2029 to Sep 1, 2033
- Notable Primary completion date: Feb 1, 2027 to Aug 1, 2028
- Study completion date: Feb 1, 2027 to Aug 1, 2029
- Start date: Feb 6, 2024 to Feb 12, 2024
- Notable Eligibility criteria expanded, about 33 wordsv4
Show 2 earlier versionsHide 2 earlier versions
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Feb 1, 2024 to Feb 6, 2024
- Site details revised
- Notable Start date: Jan 1, 2024 to Feb 1, 2024
- Primary and study completion dates: Jan 1, 2027 to Feb 1, 2027
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of participants experiencing drug-related adverse events (AEs) requiring treatment discontinuation
Timeframe: 4 years
Objective response rate (ORR) using immune Response Evaluation Criteria for Solid Tumors (RECIST 1.1)
Timeframe: 4 years
Secondary (2)
Progression-free Survival (PFS)
Overall survival (OS)
Arms and interventions
Durvalumab and DRP-104Experimental
Drugs: Durvalumab, DRP-104
Sites
1 site in 1 country
- Johns Hopkins SKCCCBaltimore, Maryland, United States